Immune Thrombocytopenic Purpura Clinical Trials

7 recruitingLast updated: May 21, 2026

There are 7 actively recruiting immune thrombocytopenic purpura clinical trials across 17 countries. Studies span Phase 3, Early Phase 1, Not Applicable, Phase 1, Phase 2. Top locations include Tianjin, Tianjin Municipality, China, Alcorcón, Mardrid, Spain, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Immune Thrombocytopenic Purpura Trials at a Glance

7 actively recruiting trials for immune thrombocytopenic purpura are listed on ClinicalTrialsFinder across 6 cities in 17 countries. The largest study group is Phase 3 with 3 trials, with the heaviest enrollment activity in Tianjin, Alcorcón, and Beijing. Lead sponsors running immune thrombocytopenic purpura studies include Takeda, Institute of Hematology & Blood Diseases Hospital, China, and New York Medical College.

Browse immune thrombocytopenic purpura trials by phase

About Immune Thrombocytopenic Purpura Clinical Trials

Looking for clinical trials for Immune Thrombocytopenic Purpura? There are currently 3 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Thrombocytopenic Purpura trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Thrombocytopenic Purpura clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)
Takeda171 enrolled112 locationsNCT06722235
Recruiting
Phase 3

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Immune Thrombocytopenic Purpura (ITP)
Takeda150 enrolled108 locationsNCT06948318
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPIdiopathic Thrombocytopenic Purpura+4 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 1

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura
New York Medical College20 enrolled1 locationNCT04323748
Recruiting
Early Phase 1

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

Autoimmune Hemolytic AnemiaEvans SyndromePrimary Immune Thrombocytopenic Purpura
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology27 enrolled1 locationNCT07441525
Recruiting
Not Applicable

TPO-RA in Primary Immune Thrombocytopenia (ITP) in Patients Older Than 14 Years

Primary Immune Thrombocytopenic Purpura
Institute of Hematology & Blood Diseases Hospital, China100 enrolled1 locationNCT04890041
Recruiting

A Two-Part Study to Assess the Effects of Ritonavir on PRN1008 Pharmacokinetics, and the Effect of PRN1008 on QTc Interval Compared to Placebo and Moxifloxacin in Healthy Participants

PemphigusImmune Thrombocytopenic Purpura
Principia Biopharma, Inc.40 enrolled1 locationACTRN12618001036202